IOVA Iovance Biotherapeuticsdata gap · 60% coveragelimited data
Health Care · Biological Products, (No Diagnostic Substances) · close $13.62 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Iovance Biotherapeutics (IOVA) has a ThetaGrade House Rating of 56/100 (grade C), ranking #70 of 150 in Health Care. Its strongest pillars are growth (86) and balance sheet (73); its weakest is cash flow (7). Data gap: 6 factors without usable data, so 60% of the method weight is covered. TTM revenue growth is 34.5% and operating margin -92.7%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, EPS growth YoY (TTM), Net debt / EBITDA, Interest coverage, P/E (inverted). Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 60% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 86| Revenue growth YoY (TTM) (22.2%) | 34.5% | 83 |
| EPS growth YoY (TTM) (0.0%)data gap | — | — |
| Revenue acceleration (11.1%) | 20.8% | 92 |
Profitability
weight 18.5% (→20.0%) · 50| Operating margin (10.7%) | -92.7% | 7 |
| 4Q gross-margin change (9.3%) | 8.9% | 100 |
Balance sheet
weight 18.5% (→20.0%) · 73| Net debt / EBITDA (0.0%)data gap | — | — |
| Current ratio (20.0%) | 4.35 | 73 |
| Interest coverage (0.0%)data gap | — | — |
Cash flow
weight 12.33% (→13.3%) · 7| FCF margin (6.7%) | -127.6% | 7 |
| FCF yield (6.7%) | -5.5% | 7 |
Valuation
weight 12.33% (→13.3%) · 13| P/E (inverted) (0.0%)data gap | — | — |
| EV/Sales (inverted) (13.3%) | 18.64× | 13 |
Technicals (EOD)
| RSI(14) | 59.9 |
| EMA 9 / 21 | 13.96 / 12.89 |
| 200-day SMA | 5.30 |
| Volume vs 20d avg | 0.68× |
| 20-day return | 35.9% |
Exit-rule monitor
- EXITRating break: House Rating below 60
- EXITBalance-sheet stress: negative free cash flow (latest FY)
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: Revenue − CostOfRevenue · Operating income: OperatingIncomeLoss · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareBasic · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close.
Get rating changes like IOVA's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is IOVA's House Rating?
- IOVA scores 56 out of 100 (grade C) as of 2026-10-16, ranking #70 of 150 Health Care stocks we cover.
- What do analysts say about IOVA?
- We do not have enough analyst-sentiment data to score this stock.
- When does IOVA report earnings next?
- IOVA's next earnings report is estimated for about 2026-11-05 (window 2026-11-02 to 2026-11-08), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is IOVA a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology